Mouse Anti-MET (C-terminus) Recombinant Antibody (CBFYH-2641) (CBMAB-H3690-FY)

Basic Information
Formulations & Storage [For reference only, actual COA shall prevail!]
Target
(Microbial infection) Acts as a receptor for Listeria monocytogenes internalin InlB, mediating entry of the pathogen into cells.
Cell migration Source: GO_Central
Cell surface receptor signaling pathway Source: UniProtKB
Endothelial cell morphogenesis Source: UniProtKB
Entry of bacterium into host cell Source: Reactome
Establishment of skin barrier Source: CAFA
Liver development Source: GO_Central
MAPK cascade Source: Reactome
Multicellular organism development Source: GO_Central
Negative regulation of autophagy Source: ParkinsonsUK-UCL
Negative regulation of guanyl-nucleotide exchange factor activity Source: CAFA
Negative regulation of hydrogen peroxide-mediated programmed cell death Source: BHF-UCL
Negative regulation of Rho protein signal transduction Source: CAFA
Negative regulation of stress fiber assembly Source: CAFA
Negative regulation of thrombin-activated receptor signaling pathway Source: CAFA
Nervous system development Source: GO_Central
Neuron differentiation Source: GO_Central
Pancreas development Source: GO_Central
Phagocytosis Source: GO_Central
Positive chemotaxis Source: UniProtKB
Positive regulation of endothelial cell chemotaxis Source: UniProtKB
Positive regulation of kinase activity Source: GO_Central
Positive regulation of microtubule polymerization Source: CAFA
Positive regulation of protein kinase B signaling Source: GO_Central
Positive regulation of transcription by RNA polymerase II Source: BHF-UCL
Semaphorin-plexin signaling pathway Source: UniProtKB
Signal transduction Source: ProtInc
Transmembrane receptor protein tyrosine kinase signaling pathway Source: GO_Central
Isoform 3: Secreted
Defects in MET may be associated with gastric cancer.
Hepatocellular carcinoma (HCC):
A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes.
Renal cell carcinoma papillary (RCCP):
A subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium.
A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
Deafness, autosomal recessive, 97 (DFNB97):
A form of non-syndromic sensorineural hearing loss with prelingual onset. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information.
Osteofibrous dysplasia (OSFD):
Disease susceptibility is associated with variants affecting the gene represented in this entry. Disease-associated variants identified in 4 families cause the deletion of exon 14. This results in the exclusion of an ubiquitination target site within the cytoplasmic domain, hence in protein stabilization. The persistent presence of MET at the cell surface in conditions of ligand-dependent activation retards osteoblastic differentiation.
A congenital disorder of osteogenesis characterized by non-neoplastic, radiolucent lesions that affect the cortical bone immediately under the periosteum. It usually manifests as a painless swelling or anterior bowing of the long bones, most commonly the tibia and fibula.
Helical: 933-955
Cytoplasmic: 956-1390
Ubiquitinated. Ubiquitination by CBL regulates MET endocytosis, resulting in decreasing plasma membrane receptor abundance, and in endosomal degradation and/or recycling of internalized receptors.
(Microbial infection) Tyrosine phosphorylation is stimulated by L.monocytogenes InlB. Tyrosine phosphorylation is maximal 10-20 minutes after treatment with InlB and disappears by 60 minutes. The phosphorylated residues were not identified.
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.
Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols
Related Products
Mouse Anti-MET Recombinant Antibody (CBYY-C2664) (CAT#: CBMAB-C4105-YY)
Mouse Anti-MET Recombinant Antibody (CBFYH-2652) (CAT#: CBMAB-H3696-FY)
Rat Anti-MET Recombinant Antibody (6F7) (CAT#: CBMAB-C8288-LY)
Rabbit Anti-MET Recombinant Antibody (CBFYM-0284) (CAT#: CBMAB-M0349-FY)
Mouse Anti-MET Recombinant Antibody (CBFYM-0335) (CAT#: CBMAB-M0408-FY)
Rabbit Anti-MET Recombinant Antibody (202) (CAT#: CBMAB-C4342-LY)
Mouse Anti-MET (AA 125-421) Recombinant Antibody (CBFYC-2948) (CAT#: CBMAB-C3024-FY)
Mouse Anti-MET Recombinant Antibody (CBXC-0674) (CAT#: CBMAB-C4145-CQ)
Rabbit Anti-MET Recombinant Antibody (CBFYM-0259) (CAT#: CBMAB-M0324-FY)
Custom Antibody Labeling
We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).
Online InquiryContact us
